塞德斯醫療 CLDX 深 滬
等待開盤 09-25 09:30:00 美东时间
31.48
+0.360
+1.16%
華盛通- 最 高31.66
- 今 開31.48
- 成交量 227.46万股
- 最 低 30.594
- 昨 收 31.12
- 總市值 24.72亿
- 52周最高 45.14
- 市盈率 靜 --
- 換手率 2.90%
- 52周最低 22.10
- 委 比 -93.29%
- 總股本 7852.95万
- 歷史最高 582.60
- 量 比 0.54
- 振 幅 3.43%
- 歷史最低 1.50
- 每 手 1
- 風險率 5.40%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 汽车地带绩后遭10家机构降目标价！最低看至3000美元；美光、微软、Meta齐获看多
今日重点评级关注：Leerink Partners：维持塞德斯医疗"跑赢大市"评级，目标价从70美元升至88美元；HC Wainwright & Co.：维持TriSalus Life Sciences"买入"评级，目标价从11美元升至12美元
09-24 16:10
美股大行评级 | Muse热度发酵，Meta目标价获大幅升至875美元；闪迪获看好至2400美元，潜在升幅约27%
今日重点评级关注：Citizens：上调Quince Therapeutics评级至"跑赢大市"，目标价77美元；康托·菲茨杰拉德：维持塞德斯医疗"超配"评级，目标价从61美元升至72美元
09-23 15:30
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease
Celldex Therapeutics Inc. (NASDAQ:CLDX) on Tuesday shared topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 clinical trials. The studies evaluate barzolvolimab for patients with chronic spontaneous urticaria (CSU) who experience inadequate symptom control using H1-antihistamines, includin...
09-23 00:25
Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72
Cantor Fitzgerald analyst Kristen Kluska maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $61 to $72.
09-22 23:33
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
Celldex reported positive Phase 3 results for barzolvolimab in chronic spontaneous urticaria (CSU), showing rapid, profound, and sustained efficacy across both dose groups. The studies met primary and key secondary endpoints at Week 12, with significant improvements in UAS7 scores and complete response rates. Barzolvolimab demonstrated strong differentiation in omalizumab-refractory and severe CSU populations, with a favorable safety profile. Eff...
09-22 10:58
美股大行评级 | 齐声看好医药股！礼来、强生、默沙东目标价均获上调；小摩大幅上调Meta目标价至820美元
今日重点评级关注：康托·菲茨杰拉德：维持SOL Strategies"超配"评级，目标价从2.8美元升至6.2美元；康托·菲茨杰拉德：维持Sui Group Holdings"超配"评级，目标价从1.7美元升至3.4美元
09-11 14:30
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $50
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $46 to $50.
09-11 01:28
Celldex to Present at Upcoming Investor Conference
Celldex announced that its management will participate in a fireside chat at the Cantor Global Healthcare Conference on September 10, 2026, at 8:00am ET. The presentation will be available via webcast on the "Events and Presentations" page of Celldex's investor website, with replays accessible for 90 days. Celldex focuses on developing innovative antibody-based therapies to treat allergic, inflammatory, and autoimmune disorders. For more informat...
09-08 20:01
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)
NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Celldex Therapeutics, Inc. (NASDAQ: CLDX) on behalf of the company's shareholders. The inve...
08-24 20:45
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
